Overview

Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer

Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
To verify the non-inferiority of exemestane compared to anastrozole in time to tumor progression (TTP), the primary efficacy endpoint, in postmenopausal women with advanced/recurrent breast cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Treatments:
Anastrozole
Exemestane